Clinical trials: Neurocognitive Disorders, Mild
Mild Cognitive Impairment
Water-based Activity to Enhance Recall in Veterans
This two-year study will evaluate the feasibility of an exercise training augmentation for cognitive training intervention to improve memory performance in Veterans with a diagnosis of amnestic Mild Cognitive Impairment (aMCI).
- Trial name
- WATER-VET (NCT02614092)
- Testing
- Water-based Activity + Cognitive Training
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Alzheimer's Disease
Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease
The investigators hypothesize that Nilotinib will be safe in individuals with mild to moderate AD. Specifically, investigators hypothesize that low daily oral doses of Nilotinib will lead to CSF penetration, CNS Abl inhibition…
- Trial name
- AD (NCT02947893)
- Testing
- Nilotinib Capsule(s) Once a Day by Mouth
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Georgetown University
Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
STIM+: PET Biomarker Education & Disclosure
When dementia is caused by AD, we refer to it as dementia of the Alzheimer's Type (DAT). The greatest risk factor for Alzheimer's Disease (AD) and DAT is advancing age, but DAT is not a normal part of aging.
- Trial name
- STIM+ (NCT04818255)
- Testing
- PET Biomarker Disclosure
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Michigan
Alzheimer Disease, Mild Cognitive Impairment
Decision Making and Implementation of Aging-in-Place/Long Term Care Plans Among Older Adults
This study seeks to better understand how older adult aging-in-place/long term care decision making and implementation is impacted by age-related changes (e.g.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Long-Term Care Planning
- Trial name
- PYL (NCT03960476)
- Testing
- PlanYourLifespan.org
- Where
- United States
- Volunteers
- 293 people
- Sponsor
- Northwestern University
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Alzheimer's Disease
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo.
- Trial name
- NCT01193608
- Testing
- AAB-003 (PF-05236812)
- Where
- 29 sites in United States, South Korea
- Volunteers
- 88 people
- Sponsor
- Pfizer
Alzheimer's Disease
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and Efficacy of donepezil in treatment of AD patients in China.
- Trial name
- STDMMAD (NCT02787746)
- Testing
- Donepezil
- Where
- China
- Volunteers
- 241 people
- Sponsor
- Beijing Friendship Hospital
Depression, Mild Cognitive Impairment
Combination Treatment Study for Memory Impairment and Depression
Patients presenting with depression (DEP) and cognitive impairment (CI), represent a unique, understudied population that is difficult to diagnose, treat and estimate prognosis.
- Trial name
- DEP-CI (NCT01658228)
- Testing
- Donepezil, Citalopram, Venlafaxine
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- New York State Psychiatric Institute
Parkinson's Disease, Mild Cognitive Impairment
Mild Cognitive Impairment in Parkinson's Disease
Mild cognitive impairment, including difficulty with solving problems, planning, attention, or recalling information, can be a significant problem for individuals with Parkinson's disease.
- Trial name
- NCT01519271
- Testing
- Exelon Patch (rivastigmine transdermal system)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Pennsylvania
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment
This study aims to develop and evaluate new in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT04206670
- Testing
- In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Alzheimer Disease, Mild Memory Disturbance
The MObile AssessMENT of Behavioral and Psychological Symptoms of Dementia in Amnestic MCI and AD (MOMENT) Study
The purpose of this research study is to learn whether it is possible and useful for caregivers to report behavioral or psychological symptoms of people with mild memory problems or Alzheimer's disease through a smartphone mobile…
- Conditions
- Alzheimer Disease, Mild Memory Disturbance, Mild Cognitive Impairment
- Trial name
- MOMENT (NCT04482036)
- Testing
- Mobile Phone Application Assessments, Standard Assessments
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alzheimer Disease
Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization product+, in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00955409
- Testing
- ACC-001(3µg) + QS21, ACC-001(10µg) + QS21, ACC-001(30µg) + QS21
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
Mild Cognitive Impairment
Brain and Cognitive Changes After Reasoning Training in Individuals With Mild Cognitive Impairment
Individuals aged 55 and older may experience negative effects of cognitive decline. The proposed research seeks to evaluate the benefits of different types of interventions: reasoning training following transcranial direct…
- Trial name
- NCT02596906
- Testing
- tDCS
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- The University of Texas at Dallas
Mild Cognitive Impairment
Preventing Loss of Independence Through Exercise (PLIÉ) in Persons With Mild Cognitive Impairment (MCI)
Nearly 1 in 10 older Americans have dementia, which is a devastating condition that leads to a progressive loss of independence and functional status.
- Trial name
- MCI PLIE (NCT03526146)
- Testing
- Behavioral: Preventing Loss of Independence through Exercise (PLIE)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of California, San Francisco
Mild Cognitive Impairment
Impact of Combined Behavioral Interventions on Cognitive Outcomes in MCI
Vast evidence supports use of physical exercise and cognitive stimulation for lowering risk for cognitive decline and dementia, with combinations of non-pharmacological interventions providing greatest promise for impacting…
- Trial name
- CBI (NCT02864069)
- Testing
- Walking Intervention, Cognitive Training Intervention, Combined Intervention
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Alzheimer's Disease
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this long term extension study is to assess safety, tolerability and immunogenicity of ACC-001 with QS-21 adjuvant in Japanese subjects with mild to moderate AD who were randomized in the preceding P2 double blind…
- Trial name
- NCT01238991
- Testing
- ACC-001
- Where
- 11 sites in Japan
- Volunteers
- 53 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD (NCT02670083)
- Testing
- Crenezumab
- Where
- 196 sites in United States, Australia and 28 more
- Volunteers
- 813 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
- Trial name
- NCT05063539
- Testing
- LY3372689
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd